Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In silico design and cell-based evaluation of two dual anti breast cancer compounds targeting Bcl-2 and GPER

20 Oct 2023

Abstract excerpt

According to WHO statistics, breast cancer (BC) disease represents about 2.3 million diagnosed and 685,000 deaths globally. Regarding histological classification of BC, the Estrogen (ER) and Progesterone (PR) receptors negative-expression cancer, named Triple-Negative BC (TNBC), represents the most aggressive type of this disease, making it a challenge for drug discovery. In this context, our research group,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Computational Drug Discovery Methods
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37863936
DOI: 10.1038/s41598-023-43860-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In silico design and cell-based evaluation of two dual anti breast cancer compounds targeting Bcl-2 and GPERPMID 37863936Read ↗

Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancerSemantic proximity Read ↗

Multitarget Design of Steroidal Inhibitors Against Hormone-Dependent Breast Cancer: An Integrated In Silico ApproachSemantic proximity Read ↗

Genistein Mediated Molecular Pharmacology, Cell-Specific Anti-Breast Cancer Mechanism with Synergistic Effect and in silico Safety MeasurementSemantic proximity Read ↗

A drug design strategy based on molecular docking and molecular dynamics simulations applied to development of inhibitor against triple-negative breast cancer by Scutellarein derivativesSemantic proximity Read ↗

Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of ActionSemantic proximity Read ↗

Molecular Docking Appraisal of Dysphania ambrosioides Phytochemicals as Potential Inhibitor of a Key Triple-negative Breast Cancer Driver GeneSemantic proximity Read ↗

Molecular docking and MD simulation approach to identify potential phytochemical lead molecule against triple negative breast cancerSemantic proximity Read ↗

Exploring target selectivity in designing and identifying PI3Kα inhibitors for triple negative breast cancer with fragment-based and bioisosteric replacement approachSemantic proximity Read ↗

Screening and identification of phytochemical drug molecules against mutant BRCA1 receptor of breast cancer using computational approaches.Semantic proximity Read ↗

Cell cycle arrest and apoptotic studies of Terminalia chebula against MCF-7 breast cancer cell line: an in vitro and in silico approachSemantic proximity Read ↗

Multi-Scale Computational Investigation of Heliotropium indicum Phytochemicals as Multi-Target Therapeutics Against Breast Cancer: Integration of Network Pharmacology, Molecular Dynamics with Free- Energy Calculation, and Machine LearningSemantic proximity Read ↗

Compounds from diverse natural origin against triple‐negative breast cancer: A comprehensive reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.